» Articles » PMID: 18363506

Expression Strategies for Short Hairpin RNA Interference Triggers

Overview
Journal Hum Gene Ther
Specialties Genetics
Pharmacology
Date 2008 Mar 28
PMID 18363506
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Since the discovery that the triggers for RNA interference (RNAi), small interfering RNAs, could mediate silencing in mammalian cells without triggering a toxic response, RNAi has become the standard tool for sequence-specific knockdown of gene expression in molecular biology. This is due in part to the development of methods for promoter-based expression of RNAi triggers that can mediate stable silencing in mammalian cells. Numerous systems with slightly different characteristics exist, but despite incredible progress in a field that moves very rapidly, challenges still remain. The biggest challenge is to successfully and safely apply RNAi in vivo. Aside from potential issues of delivery, which is one of the most important considerations, successful application of short hairpin RNAs (shRNAs) in vivo requires expression systems that yield potent and specific knockdown of the target in the absence of toxicity. With a couple of exceptions, the current systems available for shRNA expression have not generally resulted in unexpected toxicities, while still providing strong knockdown of the intended targets; however, we do not know enough about how sequence-specific off-target effects will affect various cell and tissue types, or to what extent ectopic expression of RNAi triggers will perturb the endogenous RNAi mechanisms.

Citing Articles

Delivering therapeutic RNA into the brain using extracellular vesicles.

Shirmast P, Shahri M, Brent A, Idris A, McMillan N Mol Ther Nucleic Acids. 2024; 35(4):102373.

PMID: 39618821 PMC: 11607666. DOI: 10.1016/j.omtn.2024.102373.


Engineering circular RNA for molecular and metabolic reprogramming.

Sharma N, Dwivedi P, Bhushan R, Maurya P, Kumar A, Dakal T Funct Integr Genomics. 2024; 24(4):117.

PMID: 38918231 DOI: 10.1007/s10142-024-01394-z.


Preparation and Use of shRNA for Knocking Down Specific Genes.

Jamal A, Usman S, Teh M, Waseem A Methods Mol Biol. 2024; 2849:55-72.

PMID: 38411888 DOI: 10.1007/7651_2024_515.


Progress in circRNA-Targeted Therapy in Experimental Parkinson's Disease.

Titze-de-Almeida S, Titze-de-Almeida R Pharmaceutics. 2023; 15(8).

PMID: 37631249 PMC: 10459713. DOI: 10.3390/pharmaceutics15082035.


Breast Cancer: Circular RNAs Mediating Efficacy in Preclinical Models.

Weidle U, Hsia H, Brinkmann U Cancer Genomics Proteomics. 2023; 20(3):222-238.

PMID: 37093684 PMC: 10148070. DOI: 10.21873/cgp.20377.


References
1.
Zeng Y, Wagner E, Cullen B . Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell. 2002; 9(6):1327-33. DOI: 10.1016/s1097-2765(02)00541-5. View

2.
Hannon G, Rossi J . Unlocking the potential of the human genome with RNA interference. Nature. 2004; 431(7006):371-8. DOI: 10.1038/nature02870. View

3.
Czauderna F, Santel A, Hinz M, Fechtner M, Durieux B, Fisch G . Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res. 2003; 31(21):e127. PMC: 275484. DOI: 10.1093/nar/gng127. View

4.
Lee N, Dohjima T, Bauer G, Li H, Li M, Ehsani A . Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol. 2002; 20(5):500-5. DOI: 10.1038/nbt0502-500. View

5.
Gill D, Pringle I, Hyde S . Progress and prospects: the design and production of plasmid vectors. Gene Ther. 2009; 16(2):165-71. DOI: 10.1038/gt.2008.183. View